Accepted_test

Search for possible molecular targets of new anti-tuberculosis compounds

by Kalitvanskaya M.A. | Makarov D.A. | Khandazhinskaya A.L. | Anashkina A. A | Volgograd Medical University, 400066 Volgograd, pl. Fallen fighters, 1 | Engelhardt Institute of Molecular Biology RAS, 119991, Moscow, st. Vavilova, 32 | Engelhardt Institute of Molecular Biology RAS, 119991, Moscow, st. Vavilova, 32 | Engelhardt Institute of Molecular Biology RAS, 119991, Moscow, st. Vavilova, 32; Sechenov University, 119048, Moscow, st. Trubetskaya, 8.

Abstract ID: 629

Event: BGRS-abstracts

Sections: [Sym 3] Section “Pharmacology cheminformatics and chemical biology”

The urgency of developing new anti-tuberculosis drugs is associated with the spread of M. tuberculosis strains resistant to existing drugs. In addition, the molecular mechanisms of action of anti-tuberculosis drugs are unknown. In this work, based on existing anti-tuberculosis drugs, we screened structurally similar compounds and studied their possible interaction with a number of M. tuberculosis proteins. It was found that 1-(1,4-dihydroxy-1H-benzo[d]imidazol-2-yl)-5-(piperidin-1-yl)pyrimidin-2,4(1H,3H)-dione presumably interacts with proteins 6-hydroxymethyl-7,8-dihydropteroate synthase, isocitrate lyase 3-dehydroquinate dehydratase. These results require further experimental verification.